Beigene (ONC) News Today $230.36 +22.05 (+10.59%) As of 04/11/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period BeiGene Up Over 10%, on Pace for Largest Percent Increase Since February 2024 — Data TalkApril 13 at 12:54 PM | morningstar.comGuggenheim Reiterates Buy Rating for Beigene (NASDAQ:ONC)April 12 at 2:03 AM | americanbankingnews.comAI-focused drug discovery firms rise as FDA phases out animal testingApril 11 at 3:35 PM | msn.com1ONC : Forecasting The Future: 4 Analyst Projections For BeiGeneApril 10 at 7:46 PM | benzinga.comBeigene (NASDAQ:ONC) Raised to Moderate Buy at Royal Bank of CanadaRoyal Bank of Canada raised shares of Beigene to a "moderate buy" rating in a research report on Monday.April 10 at 5:44 AM | marketbeat.comBeigene (NASDAQ:ONC) Upgraded by Royal Bank of Canada to Moderate Buy RatingRoyal Bank of Canada raised shares of Beigene to a "moderate buy" rating in a report on Monday.April 10 at 5:44 AM | marketbeat.comBeigene (NASDAQ:ONC) Stock Price Down 7.7% - What's Next?Beigene (NASDAQ:ONC) Trading Down 7.7% - Here's What HappenedApril 9, 2025 | marketbeat.comRBC Capital Initiates Coverage of BeiGene, - Depositary Receipt () (ONC) with Outperform RecommendationApril 8, 2025 | msn.comReviewing Beigene (ONC) & The CompetitionApril 8, 2025 | americanbankingnews.comBeiGene initiated with an Outperform at RBC CapitalApril 7, 2025 | msn.comBeigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 51,921 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.April 5, 2025 | marketbeat.comBeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRAApril 5, 2025 | finance.yahoo.comBeiGene liefert Update zum klinischen Entwicklungsprogramm von Ociperlimab (BGB-A1217)April 4, 2025 | de.finance.yahoo.com🌱 BeiGene halts lung cancer trial in San CarlosApril 4, 2025 | msn.comBeiGene Scraps Ociperlimab Lung-Cancer Drug CandidateApril 3, 2025 | marketwatch.comBeiGene to discontinue development program for ociperlimab (BGB-A1217)April 3, 2025 | markets.businessinsider.comBeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival BenefitApril 3, 2025 | benzinga.comBeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development ProgramApril 3, 2025 | businesswire.comBeiGene receives positive CHMP opinion for TevimbraMarch 31, 2025 | markets.businessinsider.comBeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerMarch 31, 2025 | finance.yahoo.comBeigene (NASDAQ:ONC) Stock Price Up 4.2% - What's Next?Beigene (NASDAQ:ONC) Stock Price Up 4.2% - Here's What HappenedMarch 29, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Shares Gap Up - Should You Buy?Beigene (NASDAQ:ONC) Shares Gap Up - Here's What HappenedMarch 28, 2025 | marketbeat.comBank of America Securities Keeps Their Buy Rating on BeiGene (ONC)March 24, 2025 | markets.businessinsider.comInsider Selling: Beigene, Ltd. (NASDAQ:ONC) Insider Sells 41,760 Shares of StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $261.28, for a total transaction of $10,911,052.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 21, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $10,911,052.80 in StockMarch 21, 2025 | insidertrades.comBeiGene price target raised to $259 from $207 at BernsteinMarch 13, 2025 | markets.businessinsider.comBernstein Sticks to Their Hold Rating for BeiGene (ONC)March 13, 2025 | markets.businessinsider.comBeigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 58,590 SharesBeigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 58,590 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $249.13, for a total value of $14,596,526.70. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.March 8, 2025 | marketbeat.comXiaodong Wang Sells 8,146 Shares of Beigene, Ltd. (NASDAQ:ONC) StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 8,146 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total value of $2,073,808.68. Following the sale, the insider now directly owns 5,240,882 shares of the company's stock, valued at $1,334,223,739.56. The trade was a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 7, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) Insider Sells $2,073,808.68 in StockMarch 7, 2025 | insidertrades.comInsider Selling: Beigene, Ltd. (NASDAQ:ONC) CEO Sells 101,000 Shares of StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 101,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $244.30, for a total transaction of $24,674,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.March 6, 2025 | marketbeat.comBeigene, Ltd. (NASDAQ:ONC) CEO John Oyler Sells 101,000 SharesMarch 6, 2025 | insidertrades.comFDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk ReductionMarch 5, 2025 | finance.yahoo.comBeigene (NASDAQ:ONC) Shares Gap Up - Still a Buy?Beigene (NASDAQ:ONC) Shares Gap Up - Here's What HappenedMarch 5, 2025 | marketbeat.comBeiGene, Ltd.: TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyMarch 4, 2025 | finanznachrichten.deBeiGene wins FDA nod for Tevimbra in first-line esophageal cancerMarch 4, 2025 | msn.comTEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyMarch 4, 2025 | businesswire.comBeigene (NASDAQ:ONC) Shares Gap Down After Insider SellingBeigene (NASDAQ:ONC) Shares Gap Down After Insider SellingMarch 4, 2025 | marketbeat.comBeigene (NASDAQ:ONC) Stock Rating Upgraded by Bank of AmericaBank of America upgraded Beigene from a "neutral" rating to a "buy" rating and increased their price target for the stock from $207.00 to $320.00 in a report on Monday.March 3, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: BeiGene (ONC) and Omnicell (OMCL)March 3, 2025 | markets.businessinsider.comBeiGene (ONC) Gets a Buy from J.P. MorganMarch 3, 2025 | markets.businessinsider.comBeigene FY2026 EPS Forecast Decreased by Leerink PartnrsBeigene, Ltd. (NASDAQ:ONC - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for shares of Beigene in a research report issued on Thursday, February 27th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings oMarch 3, 2025 | marketbeat.comUS$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These ResultsMarch 2, 2025 | finance.yahoo.comWhy BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025March 2, 2025 | msn.comBeiGene price target raised to $348 from $345 at GuggenheimMarch 1, 2025 | markets.businessinsider.comBeigene (NASDAQ:ONC) Price Target Raised to $313.00 at MacquarieMacquarie increased their price objective on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday.March 1, 2025 | marketbeat.comBeiGene gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 sowie Geschäftsaktualisierungen bekanntMarch 1, 2025 | businesswire.comBeigene, Ltd. (NASDAQ:ONC) Director Sells $190,535,020.00 in StockBeigene, Ltd. (NASDAQ:ONC - Get Free Report) Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now directly owns 730,642 shares of the company's stock, valued at approximately $189,966,920. This represents a 50.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.March 1, 2025 | marketbeat.comBeiGene granted orphan designation for sonrotoclaxFebruary 28, 2025 | markets.businessinsider.comBeiGene (ONC) Receives a Buy from Morgan StanleyFebruary 28, 2025 | markets.businessinsider.com Remove Ads Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Media Mentions By Week ONC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONC News Sentiment▼0.530.95▲Average Medical News Sentiment ONC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONC Articles This Week▼147▲ONC Articles Average Week Remove Ads Get Beigene News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News TAK News ARGX News BNTX News TEVA News ITCI News SMMT News GMAB News RDY News MRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONC) was last updated on 4/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beigene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
